Abpro Holdings, Inc. (ABP)
NASDAQ: ABP · Real-Time Price · USD
1.360
+0.080 (6.25%)
Jan 15, 2025, 11:59 AM EST - Market open
Company Description
Abpro Holdings, Inc., a biotechnology company, provides antibody therapeutics for cancer related issues.
Its platform DiversImmune addresses the antibody therapeutics. The company’s product candidates include ABP-102 for the treatment of breast and gastric cancer; and ABP-110 for the treatment of liver cancer.
It also offers ABP-105 for the treatment of gastric cancer and ABP 201 for vascular diseases of the eye and diabetic macular edema.
Abpro Holdings, Inc. was incorporated in 2004 and is based in Woburn, Massachusetts.
Abpro Holdings, Inc.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Ian Chan |
Contact Details
Address: 68 Cummings Park Drive Woburn, Massachusetts 01801 United States | |
| Phone | 800 396 5890 |
| Website | abpro.com |
Stock Details
| Ticker Symbol | ABP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001893219,CIK_0001670356 |
| Employer ID | 20-1546491 |
Key Executives
| Name | Position |
|---|---|
| Ian Chan | Co-Founder, President, Chief Executive Officer, Secretary and Director |
| Eugene Y. Chan M.D. | Co-Founder, Chairman and Secretary |
| Richard J. Mitrano | Senior Vice President of Finance |
| Christian Zapf | Senior Vice President of Corporate Development and General Counsel |
| Robert J. Markelewicz Jr., M.D. | Chief Medical Officer and Treasurer |